Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis

L Obici, A Meini, M Cattalini, S Chicca… - Annals of the …, 2011 - ard.bmj.com
L Obici, A Meini, M Cattalini, S Chicca, M Galliani, S Donadei, A Plebani, G Merlini
Annals of the Rheumatic Diseases, 2011ard.bmj.com
3. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in
monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin
Immunol 2009; 124: 1141–9; quiz 1150–1. 4. Simon A, Bodar EJ, van der Hilst JC, et al.
Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004; 117: 208–
10. 5. Sacré K, Brihaye B, Lidove O, et al. Dramatic improvement following interleukin 1beta
blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti …
3. Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 2009; 124: 1141–9; quiz 1150–1. 4. Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004; 117: 208–10. 5. Sacré K, Brihaye B, Lidove O, et al. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 2008; 35: 357–8. 6. Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58: 1516–20.
ard.bmj.com